A Phase 3, Open-label, Single Arm, Multicenter Study of Ravulizumab in Addition to Best Supportive Care in Pediatric Participants With Thrombotic Microangiopathy (TMA) After Hematopoietic Stem Cell Transplantation (HSCT)
Latest Information Update: 09 Jul 2024
At a glance
- Drugs Ravulizumab (Primary)
- Indications Thrombotic microangiopathy
- Focus Registrational; Therapeutic Use
- Sponsors Alexion AstraZeneca Rare Disease
- 20 Jun 2024 Planned End Date changed from 30 Jun 2025 to 30 May 2025.
- 20 Jun 2024 Planned primary completion date changed from 30 Dec 2024 to 29 Nov 2024.
- 26 Feb 2024 Planned End Date changed from 11 Aug 2025 to 30 Jun 2025.